Read now


Discover the conference highlights

Real-world comparison of dimethyl fumarate and teriflunomide for treatment of multiple sclerosis


  • Real-world data show that dimethyl fumarate (DMF) is associated with lower annualized relapse rates (ARR), higher relapse-free survival and lower incidence of discontinuation due to disease breakthrough versus teriflunomide (TFL) in relapsing-remitting multiple sclerosis (RRMS).

Why this matters

  • Dimethyl fumarate and teriflunomide are often used as initial therapy for RRMS, yet evidence of comparative effectiveness for the two treatments is limited.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.